Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.

Forty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infec...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, H., Scarffe, J. H., Sutton, R. N., Hickmott, E., Brigden, D., Burke, C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1984
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976928/
https://www.ncbi.nlm.nih.gov/pubmed/6378236
_version_ 1782135155322781696
author Anderson, H.
Scarffe, J. H.
Sutton, R. N.
Hickmott, E.
Brigden, D.
Burke, C.
author_facet Anderson, H.
Scarffe, J. H.
Sutton, R. N.
Hickmott, E.
Brigden, D.
Burke, C.
author_sort Anderson, H.
collection PubMed
description Forty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection. The dose of acyclovir was 200 mg four times daily for the duration of chemotherapy (six weeks). Of the 40 evaluable patients, 20 were randomised to each arm. Prophylactic oral acyclovir significantly reduced the incidence of clinical HSV infection from 60% on placebo to 5% acyclovir (P less than 0.001), and the incidence of viral isolates from 70% on placebo to 5% on acyclovir (P less than 0.001).
format Text
id pubmed-1976928
institution National Center for Biotechnology Information
language English
publishDate 1984
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19769282009-09-10 Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Anderson, H. Scarffe, J. H. Sutton, R. N. Hickmott, E. Brigden, D. Burke, C. Br J Cancer Research Article Forty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection. The dose of acyclovir was 200 mg four times daily for the duration of chemotherapy (six weeks). Of the 40 evaluable patients, 20 were randomised to each arm. Prophylactic oral acyclovir significantly reduced the incidence of clinical HSV infection from 60% on placebo to 5% acyclovir (P less than 0.001), and the incidence of viral isolates from 70% on placebo to 5% on acyclovir (P less than 0.001). Nature Publishing Group 1984-07 /pmc/articles/PMC1976928/ /pubmed/6378236 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Anderson, H.
Scarffe, J. H.
Sutton, R. N.
Hickmott, E.
Brigden, D.
Burke, C.
Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
title Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
title_full Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
title_fullStr Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
title_full_unstemmed Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
title_short Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.
title_sort oral acyclovir prophylaxis against herpes simplex virus in non-hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. a randomised double blind, placebo controlled trial.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976928/
https://www.ncbi.nlm.nih.gov/pubmed/6378236
work_keys_str_mv AT andersonh oralacyclovirprophylaxisagainstherpessimplexvirusinnonhodgkinlymphomaandacutelymphoblasticleukaemiapatientsreceivingremissioninductionchemotherapyarandomiseddoubleblindplacebocontrolledtrial
AT scarffejh oralacyclovirprophylaxisagainstherpessimplexvirusinnonhodgkinlymphomaandacutelymphoblasticleukaemiapatientsreceivingremissioninductionchemotherapyarandomiseddoubleblindplacebocontrolledtrial
AT suttonrn oralacyclovirprophylaxisagainstherpessimplexvirusinnonhodgkinlymphomaandacutelymphoblasticleukaemiapatientsreceivingremissioninductionchemotherapyarandomiseddoubleblindplacebocontrolledtrial
AT hickmotte oralacyclovirprophylaxisagainstherpessimplexvirusinnonhodgkinlymphomaandacutelymphoblasticleukaemiapatientsreceivingremissioninductionchemotherapyarandomiseddoubleblindplacebocontrolledtrial
AT brigdend oralacyclovirprophylaxisagainstherpessimplexvirusinnonhodgkinlymphomaandacutelymphoblasticleukaemiapatientsreceivingremissioninductionchemotherapyarandomiseddoubleblindplacebocontrolledtrial
AT burkec oralacyclovirprophylaxisagainstherpessimplexvirusinnonhodgkinlymphomaandacutelymphoblasticleukaemiapatientsreceivingremissioninductionchemotherapyarandomiseddoubleblindplacebocontrolledtrial

Ejemplares similares